Last Updated: 14 Sep 2024
Executive Summary
Harvard Bioscience Inc. (HBIO) is a life sciences company that provides technologies and products for drug development. The company's stock has underperformed the market in recent years, and is currently trading at $2.88. Despite this, analysts remain bullish on the stock, with a consensus target price of $6.25.
Company Overview
Harvard Bioscience was founded in 1981 and is headquartered in Holliston, Massachusetts. The company develops, manufactures, and sells a range of products and services for the life sciences industry, including cell culture media, reagents, and instruments. Harvard Bioscience's products are used by researchers in academia, government, and industry to study cell biology, drug discovery, and other areas of life sciences.
Fundamental Analysis
Harvard Bioscience's financial performance has been mixed in recent years. The company's revenue has declined in each of the past three years, and its net income has been negative for the past two years. However, the company's gross profit margin has improved in recent quarters, and its operating expenses have declined.
Analysts expect Harvard Bioscience to return to profitability in 2024. The company's revenue is expected to grow by 5% in 2024, and its net income is expected to turn positive. Analysts also expect the company's gross profit margin to continue to improve, and its operating expenses to decline.
Technical Analysis
Harvard Bioscience's stock price has been in a downtrend since 2021. The stock has broken below its 50-day and 200-day moving averages, and is currently trading near its 52-week low. The stock's relative strength index (RSI) is also below 30, which indicates that the stock is oversold.
Short Term Outlook
Analysts are mixed on Harvard Bioscience's short-term outlook. Some analysts believe that the stock is oversold and is due for a rebound. Other analysts believe that the stock will continue to decline in the near term.
Long Term Outlook
Analysts are more bullish on Harvard Bioscience's long-term outlook. The company's products are used in a variety of life sciences applications, and the demand for these products is expected to grow in the coming years. Analysts believe that Harvard Bioscience is well-positioned to benefit from this growth.
Analyst Recommendations
The consensus analyst recommendation for Harvard Bioscience is "buy." Two analysts have a "buy" rating on the stock, and none have a "sell" rating. The consensus target price for the stock is $6.25.
